NASDAQ: CINGCingulate Inc Stock
$3.96-0.13 (-3.18%)
Updated Mar 21, 2025
CING Price
$3.96
Fair Value Price
N/A
Market Cap
$12.72M
52 Week Low
$1.80
52 Week High
$20.83
P/E
-0.08x
P/B
1.06x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$16.35M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.13
Operating Cash Flow
-$17M
Beta
1.08
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
CING Overview
Cingulate Inc. is a clinical-stage biopharmaceutical company developing treatments for attention deficit/hyperactivity disorder. The company's lead candidates are CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine). CTx-2103 is being developed for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, KS.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CING's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
CING
Ranked#257 of 483
Ranked#257 of 483
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.49 | A | |
| $138.76 | A | |
| $7.75 | A |
Be the first to know about important CING news, forecast changes, insider trades & much more!
CING News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CING scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CING is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
CING is good value based on its book value relative to its share price (1.06x), compared to the US Biotechnology industry average (4.69x)
P/B vs Industry Valuation
CING is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more CING due diligence checks available for Premium users.
Valuation
CING price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.08x
Industry
-110.14x
Market
31.55x
CING price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.06x
Industry
4.69x
CING is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CING's financial health
Profit margin
Revenue
$0.0
Net Income
-$3.2M
Profit Margin
0%
CING's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$13.6M
Liabilities
$1.5M
Debt to equity
0.13
CING's short-term assets ($11.34M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CING's short-term assets ($11.34M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CING's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$3.9M
Investing
$140.8k
Financing
$13.4M
CING's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CING vs Biotech Stocks
Cingulate Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.